12 Hot Stocks to Buy According to Analysts

Page 6 of 11

6. TG Therapeutics, Inc. (NASDAQ:TGTX)

Average Upside Potential: 46.86%

Gain Over Past 6 Months: 30.02%

TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of novel treatments for B-cell diseases. While the company has a research pipeline encompassing different investigational medicines, it has secured U.S. Food and Drug Administration (FDA) approval for BRIUMVI for the treatment of adults with multiple sclerosis (RMS).

The firm’s novel therapy for relapsing forms of multiple sclerosis, BRIUMVI, has been quite a performer. While TGTX is engaging in label expansion opportunities for BRIUMVI entering into the new year, it could enhance the market share as well as the drug’s competitive position. Regarding TG Therapeutics, ClearBridge Small Cap Growth Strategy stated the following in its Q4 2024 investor letter:

“TG Therapeutics is a commercial-stage biotechnology company focused on multiple sclerosis (MS), a significant chronic disease end market. Its lead product, Briumvi, has the potential to grow its market share significantly within the largest drug class in the $8 billion MS market.”

While TG Therapeutics, Inc. (NASDAQ:TGTX) posted preliminary revenues for the fourth quarter and full year 2024 which surpassed the firm’s and consensus estimates,  primarily driven by the sales of BRIUMVI, the stock received a Buy rating from H.C. Wainwright analyst Edward White who believes in the aforementioned factors driving a strong financial outlook for the company.

Page 6 of 11